RVLPQ (RVL Pharmaceuticals) WACC %:20.64% (As of Jun. 24, 2026)


RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals WACC %?

RVL Pharmaceuticals RVLPQ -90.00% 12 WACC % is 20.64% as of Jun. 24, 2026. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

As of today (2026-06-24), RVL Pharmaceuticals's weighted average cost of capital is 20.64%%. RVL Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). RVL Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


RVL Pharmaceuticals  (OTCPK:RVLPQ) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, RVL Pharmaceuticals's weighted average cost of capital is 20.64%%. RVL Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). RVL Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

RVL Pharmaceuticals WACC % Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals WACC % Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
WACC %
Get a 7-Day Free Trial 7.65 7.12 4.81 7.30 7.63

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.27 7.95 7.63 8.93 11.02

RVLPQ vs SNPX, THAR, SLRX: WACC % Comparison

For the Biotechnology subindustry, RVL Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's WACC % distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's WACC % falls into.


RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RVL Pharmaceuticals WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, RVL Pharmaceuticals's market capitalization (E) is $0.000 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Jun. 2023, RVL Pharmaceuticals's latest one-year quarterly average Book Value of Debt (D) is $54.891 Mil.
a) weight of equity = E / (E + D) = 0.000 / (0.000 + 54.891) = 0
b) weight of debt = D / (E + D) = 54.891 / (0.000 + 54.891) = 1

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.406%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. RVL Pharmaceuticals's beta is -11.1162.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.406% + -11.1162 * 6% = -62.2912%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Jun. 2023, RVL Pharmaceuticals's interest expense (positive number) was $11.375 Mil. Its total Book Value of Debt (D) is $54.891 Mil.
Cost of Debt = 11.375 / 54.891 = 20.7229%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -0.277 / -68.543 = 0.4%.

RVL Pharmaceuticals's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0*-62.2912%+1*20.7229%*(1 - 0.4%)
=20.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 20.64% mean?
RVL Pharmaceuticals (RVLPQ) has a WACC % of 20.64% as of Jun. 24, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' WACC % too high?
RVL Pharmaceuticals' current WACC % is 20.64%. The Biotechnology industry median WACC % is 10.06. RVL Pharmaceuticals' value of 20.64% is 105.2% above this industry median. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' WACC % compare to SNPX and THAR?
RVL Pharmaceuticals' WACC % of 20.64% can be compared against companies in the Biotechnology industry. The industry median WACC % is 10.06. RVL Pharmaceuticals' value of 20.64% is 105.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.06, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RVL Pharmaceuticals's current WACC % of 20.64% is 105.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on RVL Pharmaceuticals and its competitors. For the Biotechnology industry, the median WACC % is 10.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RVL Pharmaceuticals's current WACC % is 20.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current WACC % of 20.64%. The current WACC % is 20.64% and 105.2% above the Biotechnology industry median of 10.06. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current WACC % is 20.64% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price